UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2023
Synaptogenix, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-40458 | 46-1585656 |
(State or other jurisdiction
of incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
1185 Avenue of the Americas, 3rd Floor
New York, New York 10036
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (973) 242-0005
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading
Symbol(s) | | Name of each exchange on which
registered |
| Common Stock, $0.0001 par value per share | | SNPX | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company. x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan
On December 20, 2023, Synaptogenix, Inc. (“we,” “us” and “our”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, our stockholders approved an amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan (the “Plan”). The Plan was amended to increase the total number of shares of our common stock, par value $0.0001 per share (the “Common Stock”), authorized for issuance thereunder from 1,375,000 shares of Common Stock to an aggregate of 4,375,000 shares of Common Stock.
A detailed summary of the amendment to the Plan is set forth in our Definitive Proxy Statement on Schedule 14A for the Annual Meeting filed with the U.S. Securities and Exchange Commission on November 13, 2023 (the “Proxy Statement”) under the caption “Proposal No. 3 - Approval of an Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan.” That detailed summary of the amendment to the Plan and the foregoing description of the amendment to the Plan are qualified in their entirety by reference to the full text of the amendment to the Plan, which is filed hereto as Exhibit 10.1 and incorporated by reference into Item 5.02 of this Current Report on Form 8-K.
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
At the Annual Meeting, the holders of 11,943,046 shares of our Common Stock, or approximately 58.57% of our outstanding shares of Common Stock, were represented in person or by proxy and, therefore, a quorum was present. At the Annual Meeting, our stockholders considered four proposals, which are described briefly below and in more detail in the Proxy Statement. The final voting results for each proposal are set forth below.
Proposal 1 - Election of Directors
Our stockholders voted to elect two directors to hold office until the 2026 annual meeting of stockholders, and until their respective successors are elected and qualified, by the following votes:
| Nominee | | For | | | Withheld | | | Broker Non-Votes | |
| Alan Tuchman | | | 4,505,521 | | | | 1,451,157 | | | | 5,986,368 | |
| Daniel L. Alkon | | | 4,728,376 | | | | 1,228,302 | | | | 5,986,368 | |
Proposal 2 – Board Authorization to Effect a Reverse Stock Split
Our stockholders voted to authorize our board of directors (the “Board”) to effect one reverse stock split of our outstanding shares of Common Stock, at a ratio between 1-for-8 and 1-for-25 (or any number in between), at such time, if any, as our Board shall determine, in its sole discretion.
| Shares Voted For | | | Shares Voted Against | | | Abstentions | |
| | 8,661,349 | | | | 3,093,253 | | | | 188,441 | |
As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.
Proposal 3 - Approval of Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan
Our stockholders voted to approve an amendment to our Plan to increase the total number of shares of Common Stock authorized for issuance thereunder from 1,375,000 shares of Common Stock to an aggregate of 4,375,000 shares of Common Stock by the following votes:
| Shares Voted For | | | Shares Voted Against | | | Abstentions | | | Broker Non-Votes | |
| | 3,356,208 | | | | 2,324,244 | | | | 276,226 | | | | 5,986,368 | |
Proposal 4 - Ratification of Selection of Independent Registered Public Accounting Firm.
The ratification of appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
| Shares Voted For | | | Shares Voted Against | | | Abstentions | |
| | 10,660,952 | | | | 994,599 | | | | 287,495 | |
As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibits are filed as part of this report:
# Management contract or compensatory plan or arrangement.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: December 21, 2023 | By: | /s/ Robert Weinstein |
| | Name: | Robert Weinstein |
| | Title: | Chief Financial Officer |
